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Fig. 1, clinically relevant? I would like to know a true p
value rather than p < 0.05. In Fig. 2 showing the change
in TLR-9 expression level, it appears that each pretreat-
ment level decreased at the end of the study. I wonder
why there is no statistical diﬀerence between pre- and
post-treatment expression levels of TLR-9. Recent ﬁnd-
ings suggest that Gram-positive bacteria, their compo-
nents or products, and their receptors such as TLR-2
and TLR-9 rather than endotoxin and TLR-4 have
more important roles in the development of bacterial
infection associated with cirrhosis [3].
Next, I would like to raise an issue regarding the
method for ex vivo endotoxin-stimulated cytokine pro-
duction. The endotoxin concentration used for the study
appears extremely high, more than 1000-fold higher
than endotoxaemia observed in patients with cirrhosis.
I would like to ask the authors the reason for using clin-
ically irrelevant high dose endotoxin in the study. In the
section of discussion, the authors mention that the lack
of adverse events associated with the administration of
probiotic preparation is evidenced by no change in clin-
ical and laboratory parameters during the study. I think
that no alteration in hepatic function during the study
period may have to be attributed to the insuﬃcient clin-
ical eﬃcacy of probiotic administration.
As well as with liver cirrhosis, bacterial overgrowth
and reduced barrier function in the gut are associated
with severe acute pancreatitis, predisposing to the devel-
opment of infectious complications. In 2008, a random-
ised clinical trial (RCT) assessing the eﬀects of probiotic
prophylaxis in 296 patients with predicted severe acute
pancreatitis resulted in unexpected increased 90-day
Letters to the Editor / Journal ofmortality associated with probiotic administration
(16% versus 6% in control patients) [4]. Although the ex-
act mechanism is uncertain, fatal bowel ischaemia con-
tributed to increased deaths in the probiotic group. I
agree with the need for RCT to evaluate the eﬃcacy of
probiotics or probiotic cocktails in cirrhosis, but it
should be done with caution.
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We would like to thank Dr. Fujita for critically read-
ing our paper about the eﬀect of the probiotic, Lactoba-
cillus casei Shirota on innate immune function in
patients with alcoholic cirrhosis. We would like to take
the opportunity to answer the questions raised in this
Letter to the Editor. Five points were raised.
1. Signiﬁcance of a 25% increase in phagocytic
capacity: We feel that a complete normalization of
phagocytic capacity observed in our study from a level
that represented only 75% of the normal level is likely
to be clinically important [1]. Several studies in diseases
other than cirrhosis have shown that even a small in-
crease in neutrophil phagocytosis is clinically relevant.
Healing of diabetic foot infections was associated with
a 14.8% absolute increase in phagocytic capacity [2].Treatment with granulocyte-colony-stimulating factor
improved phagocytic capacity by 4.1–13.8% in various
clinical conditions (neutropenic children, septic patients,
severe burns, diabetic foot infections, surgical patients
on intensive care) which was associated with clinical
beneﬁts [3–8]. However, we agree with Dr. Fujita that
further studies in larger patient cohorts are warranted
to ultimately prove the clinical signiﬁcance of our obser-
vation. The exact p-value for phagocytic capacity before
and after supplementation with Lactobacillus casei Shi-
rota for 4 weeks was p = 0.045.
2. TLR 9 expression: Dr. Fujita is right that there is a
trend towards a decrease in TLR9 expression, however,
with the correct statistical test (paired-t-test) only a
p = 0.17 could be achieved. This is likely to be due to
the relatively small sample size. We also agree that our
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contributing to neutrophil dysfunction in alcoholic cir-
rhosis. Indeed, we state in the discussion that our data
suggest the presence of increased microbial products in
the bloodstream of patients with alcoholic cirrhosis
which is in accordance with previously published data
on evidence of bacterial DNA in cirrhosis [9,10].
3. Ex vivo endotoxin stimulation: We have chosen this
concentration because it has been used previously in a
study investigating monocyte function in patient with
acute-on-chronic liver failure [11]. It is correct that mea-
sured endotoxin concentrations in patients’ plasma are
signiﬁcantly lower, however it is also well known that
plasma contains various inhibitors of endotoxin, which
makes the analysis and interpretation of absolute endo-
toxin levels diﬃcult [12].
4. The type of probiotic used: As we stated in the pa-
per, in our study we did not observe any adverse events
and we also saw no change in white blood cell count or
C-reactive protein, indicating to us that Lactobacillus
casei Shirota does not exert any proinﬂammatory stimu-
lus in our patients. With respect to liver function, one
would not expect to see changes over a short period in
patients with stable cirrhosis. However, in our study
one patient improved from Child class C to B and an-
other from Child class B to A. Patient numbers are of
course too small to draw any conclusion from this.
ALT levels were normal in most of the patients at the
beginning and throughout the study, indicating that
we have chosen truly stable cirrhotic patients.
5. Safety of probiotics:We are aware of the discussion
on safety of probiotics following publication of the
study in patients with severe pancreatitis earlier this year
[13]. In this publication, a combination of six diﬀerent
probiotic strains was administered twice daily over a
nasojejunal tube. This protocol is completely diﬀerent
to our protocol where a single probiotic bacterial strain
was consumed three times a day as a milk drink. There-
fore these two studies cannot be compared easily. How-
ever, we agree that in trials with probiotics, safety has to
be studied carefully, as with every other medication.
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